NCT07210671 Prospective Evaluation of the Treatment of Cancer Associated Superficial Venous
| NCT ID | NCT07210671 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Condition | Superficial Vein Thrombosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,576 participants |
| Start Date | 2025-11-10 |
| Primary Completion | 2027-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,576 participants in total. It began in 2025-11-10 with a primary completion date of 2027-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Superficial venous thrombosis (SVT) is very common in clinical practice. What's more, around 15- 20% of SVTs occur in the context of cancer. Today, cancer patients are excluded from therapeutic trials for DVT. There is therefore no high-level evidence-based treatment recommendation for these patients. Recent data suggest that the course of cancer-associated DVT is similar to that of cancer-associated deep vein thrombosis (DVT). However, there are currently few prospective data on the evolution of cancer-associated DVT in relation to the treatment used. Due to the absence of clear recommendations of treatment in case of SVT associated with cancer the investigators will perform a prospective observational study to evaluate the efficacy of different regiment of anticoagulant treatment ordered in clinical practice.
Eligibility Criteria
Inclusion Criteria: * Patient over 18 * Patient affiliated to a social security scheme * Patient who understands French * Patient with superficial venous thrombosis of the lower and upper limbs confirmed by a Doppler ultrasound less than one month old. * Patient with active cancer: * Cancer treatment within the last 6 months, * Detectable tumor disease, cancer treatment within the last 6 months, ongoing hormone therapy for cancer, palliative cancer. * The patient has received potentially non-curative cancer treatment (notably palliative chemotherapy). * Progression shows that the cancer treatment was not curative (due to recurrence or progression under treatment) (particularly in the case of recurrence after surgery) Exclusion Criteria: * Patients under legal protection * Patients with concomitant pulmonary embolism * Patient with proximal or distal deep vein thrombosis * Patient treated with anticoagulant therapy for another indication * Patient with a contraindication to anticoagulation: Thrombocytopenia less than 30,000 elements/mm3, active bleeding or history of severe bleeding. * Patient opposed to participation in research
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07210671 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Superficial Vein Thrombosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07210671 currently recruiting?
Yes, NCT07210671 is actively recruiting participants. Contact the research team at soudet.simon@chu-amiens.fr for enrollment information.
Where is the NCT07210671 trial being conducted?
This trial is being conducted at Amiens, France.
Who is sponsoring the NCT07210671 clinical trial?
NCT07210671 is sponsored by Centre Hospitalier Universitaire, Amiens. The trial plans to enroll 1,576 participants.